New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareVesugen vs AICAR

Vesugen vs AICAR

Side-by-side comparison of key properties, dosing, and research.

Anti-Aging & Longevity
Vesugen
Anti-Aging & LongevityFat Loss & Metabolic
AICAR
Summary
Vesugen is a tripeptide bioregulator (Lys-Glu-Asp) developed by Professor Vladimir Khavinson, tissue-specific for blood vessels and the vascular endothelium. It supports endothelial cell function, promotes vascular wall integrity, and is studied for atherosclerosis prevention, vascular aging, and cardiovascular health maintenance. It is one of the more broadly applicable Khavinson bioregulators given the ubiquity of vascular tissue.
AICAR is a cell-permeable AMP analog that activates AMPK (AMP-activated protein kinase) — the master metabolic switch that triggers fat burning, mitochondrial biogenesis, and adaptations normally only achieved through exercise. It has been called the 'exercise in a pill' compound.
Half-Life
Short (minutes); sustained gene-regulatory effects
~2–3 hours
Admin Route
SubQ, Oral
SubQ, IV
Research
Typical Dose
10 mg per day
25–50 mg
Frequency
Daily for 10–30 days
3–5 times per week
Key Benefits
  • Supports vascular endothelial cell function and integrity
  • May reduce endothelial inflammation and dysfunction
  • Anti-aging effects on blood vessel walls
  • Potential benefits in early atherosclerosis and vascular aging
  • Supports nitric oxide-mediated vascular tone
  • Reduces endothelial apoptosis from oxidative stress
  • Complementary to Cardiogen and Epithalon in cardiovascular longevity protocols
  • AMPK activation mimics aerobic exercise adaptations
  • Increased fat oxidation and endurance
  • Mitochondrial biogenesis (PGC-1alpha)
  • Improved insulin sensitivity and glucose metabolism
  • Anti-inflammatory effects
  • Potential cardiac protection during ischemia
  • Synergistic with actual exercise training
  • Reduces hepatic glucose production
Side Effects
  • Generally well tolerated
  • Mild injection site reactions
  • No significant vascular adverse events reported at standard doses
  • Hypoglycemia risk
  • Lactic acidosis at high doses (animal data)
  • Injection site irritation
Stacks With